Calls for papers
-
According to Tiziana Life Sciences, the FDA has cleared the company’s IND to allow clinical development of intranasal foralumab in Alzheimer’s disease. Earlier this year, Tiziana announced plans to develop foralumab, an intranasal anti-CD3 monoclonal antibody,… Read more . . .
-
Posted on OINDPnews on August 16, 2023 University: Texas State University College of Health Professions Description:The Aerosol Medicine Research Laboratory at the Department of Respiratory Care seeks a motivated Postdoctoral Research Fellow to join our team. Aspiring… Read more . . .
-
Marinomed Biotech has announced that its Solv4U unit is working with SPH Sine Pharmaceutical Laboratories to develop an OINDP formulation using Marinomed’s Marinosolv solubility enhancement technology. According to Marinomed, a feasibility study has been completed,… Read more . . .
-
Silo Pharma said that it is planning to develop an intranasal formulation of its SPC-15, which includes “ketamine compositions,” for the prevention and treatment of stress disorders, including anxiety and PTSD. The formulation was developed… Read more . . .
-
Avalyn Pharma, which is developing inhaled formulations of pirfenidone and nintedanib for the treatment of pulmonary fibrosis, has announced the appointment of former Altavant Sciences Chief Medical Officer Howard M. Lazarus as Chief Medical Officer. Lazarus’s… Read more . . .
-
Vistagen has announced that the Phase 3 PALISADE-2 public speaking challenge trial of PH94B fasedienol nasal spray in subjects with social anxiety disorder met its primary and secondary endpoints. The company announced the initiation of… Read more . . .
-
The UK’s Life Sciences Innovation Manufacturing Fund, which provides public/private investment to the life sciences industry, has awarded a grant to CDMO Kindeva Drug Delivery. According to a UK government press release, “The investment will create… Read more . . .
-
Missoula, Montana-based Inimmune Corporation has announced the initiation of Phase 1/1b trial of its INI-2004 intranasal toll-like receptor 4 agonist, which the company is developing for the treatment of allergic rhinitis. According to the company,… Read more . . .
-
Viatris and Kindeva Drug Delivery have announced the launch of Breyna budesonide / formoterol fumarate MDI, a generic version of AstraZeneca’s Symbicort, for the treatment of asthma in patients aged 6 and over and for the treatment… Read more . . .
-
Marinomed Biotech said that its partner M8 Pharmaceuticals has received marketing authorization for Carragelose iota-carrageenan nasal spray in Mexico. M8 acquired the rights to market the nasal spray in Mexico and Brazil in 2021. According… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland